To further the experiments in FAD models, we believe that investigating the ability of Gal-3 inhibitors to prevent Aβ-plaque formation will tell us whether there is potential for Galectin-3 as a target in AD. This evidence concerns the gene LGALS3 and Alzheimer disease.